Search company, investor...

Predict your next investment

Chengwei Capital company logo
Venture Capital
chengwei.com

Investments

155

Portfolio Exits

20

Funds

6

About Chengwei Capital

Chengwei Capital, founded in 1999 and based in Shanghai, China, is a venture capital firm targeting investments in the following sectors: communication software, enterprise software, financial services, IC design, niche component manufacturing, healthcare, and media sectors. Geographically, Chengwei Capital prefers investments in China.

Headquarters Location

Building C No. 33, Lane 672, Changle Road, Jing'an District

Shanghai, Shanghai, 200040,

China

021-54048566

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Research containing Chengwei Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Chengwei Capital in 1 CB Insights research brief, most recently on Nov 10, 2021.

Latest Chengwei Capital News

Full-Life Technologies Raises USD $47.3M in Series B Funding

Jan 4, 2024

Full-Life Technologies , a Shanghai, China-based radiotherapeutics company, raised USD $63.3M in funding. The round, which included $47.3M in Series B equity financing and $16M in loan facilities, saw participation from Prosperity7 Ventures and an undisclosed healthcare specialist investor, along with new investors Sky9 Capital, Summer Capital, and GuanghuaWutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Junson Capital. The financing will advance development of the company’s radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has secured more than $110M funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies. Full-Life Technologies is a global radiotherapeutics company with operations in Belgium, Germany, and China, which seeks to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. Since completion of its Series A equity financing in 2022, Full-Life has achieved multiple significant milestones, including but not limited to: Advancing the company’s lead drug candidate, 225Ac-FL-020, towards Phase I clinical trials in metastatic castration-resistant prostate cancer (mCRPC) patients. Clinical trials are planned to start in both Europe and the U.S. in early 2024. Full-Life’s PSMA-targeting vector, FL-020, is specifically designed to deliver the highly potent alpha-emitter, Actinium-225. Assembling a pre-clinical portfolio including both first-in-class and best-in-class programs as well as development of the novel UniRDCTM discovery platform. UniRDCTM is a proprietary platform established to streamline the discovery process of RDC. Acquiring a 17,000 square meter of land in the Walloon region of Belgium, obtaining the required construction permit, and beginning construction of a 4,000 square meter state-of-the-art GMP-level radiopharmaceutical production facility. The facility is designed to advance Full-Life’s end-to-end solution and manufacture a broad spectrum of radiopharmaceuticals. FinSMEs 04/01/2024

Chengwei Capital Investments

155 Investments

Chengwei Capital has made 155 investments. Their latest investment was in Full-Life as part of their Series B on January 03, 2024.

CBI Logo

Chengwei Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/3/2024

Series B

Full-Life

$47.3M

No

2

11/30/2023

Seed VC

Perpetual Medicines

$8M

Yes

4

11/7/2023

Seed VC - II

Douch

Yes

2

9/25/2023

Series B

Subscribe to see more

Subscribe to see more

10

7/28/2023

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/3/2024

11/30/2023

11/7/2023

9/25/2023

7/28/2023

Round

Series B

Seed VC

Seed VC - II

Series B

Series C

Company

Full-Life

Perpetual Medicines

Douch

Subscribe to see more

Subscribe to see more

Amount

$47.3M

$8M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

2

10

10

Chengwei Capital Portfolio Exits

20 Portfolio Exits

Chengwei Capital has 20 portfolio exits. Their latest portfolio exit was AIMACH Automation on June 13, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/13/2022

IPO

$99M

Public

1

1/27/2022

IPO

$99M

Public

1

2/26/2021

Acquired

$99M

6

7/9/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/8/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/13/2022

1/27/2022

2/26/2021

7/9/2020

11/8/2019

Exit

IPO

IPO

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

6

10

10

Chengwei Capital Acquisitions

1 Acquisition

Chengwei Capital acquired 1 company. Their latest acquisition was AsiaInfo Linkage on January 15, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/15/2014

Growth Equity

$99M

Take Private

1

Date

1/15/2014

Investment Stage

Growth Equity

Companies

Valuation

$99M

Total Funding

Note

Take Private

Sources

1

Chengwei Capital Fund History

6 Fund Histories

Chengwei Capital has 6 funds, including Chengwei Preferred Holdings 2016.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/3/2016

Chengwei Preferred Holdings 2016

Multi-Stage Venture Capital

Closed

$452.77M

1

12/31/2004

Chengwei Evergreen Fund

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2000

Chengwei Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Chengwei Ventures Evergreen Advisors Fund

Subscribe to see more

Subscribe to see more

10

Fund9

Subscribe to see more

Subscribe to see more

10

Closing Date

2/3/2016

12/31/2004

12/31/2000

Fund

Chengwei Preferred Holdings 2016

Chengwei Evergreen Fund

Chengwei Fund I

Chengwei Ventures Evergreen Advisors Fund

Fund9

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$452.77M

$99M

$99M

Sources

1

10

10

10

10

Chengwei Capital Team

5 Team Members

Chengwei Capital has 5 team members, including , .

Name

Work History

Title

Status

Shimo Li

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Shimo Li

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.